Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.
Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.
复制标题
DOI：
10.1016/j.jalz.2016.09.014
复制
发表时间：
2017-01
影响因子：
14
通讯作者：
Hampel, Harald
中科院分区：
文献类型：
--
作者：
O'Bryant, Sid E.;Mielke, Michelle M.;Rissman, Robert A.;Lista, Simone;Vanderstichele, Hugo;Zetterberg, Henrik;Lewczuk, Piotr;Posner, Holly;Hall, James;Johnson, Leigh;Fong, Yiu-Lian;Luthman, Johan;Jeromin, Andreas;Batrla-Utermann, Richard;Villarreal, Alcibiades;Britton, Gabrielle;Snyder, Peter J.;Henriksen, Kim;Grammas, Paula;Gupta, Veer;Martins, Ralph;Hampel, Harald
在过去的十年中，人们已经看到了大量增加的研究集中在确定血液为基础的生物标志物，在阿尔茨海默病（AD）的效用。基于血液的生物标志物具有时间和成本效益以及降低侵入性和增加患者接受度的显著优势。尽管有这些优势和不断增加的研究努力，但该领域一直受到缺乏可重复性以及将基础发现推向临床应用的不明确路径的阻碍。在这里，我们回顾了最近的文献在AD血液为基础的生物标志物，以提供一个当前的最先进的。此外，提出了一个合作模式，利用学术和行业的优势，以促进该领域在移动过去的发现只有工作和临床使用。提供了关键资源。这种新的公私合作模式旨在规避传统的交接模式，并为AD和其他神经退行性疾病的生物标志物科学的发展提供一个明确而有用的范例。
The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer’s disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility as well as an unclear path for moving basic discovery towards clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state-of-the-art. Additionally, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and towards clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional hand-off model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.
登录
查看更多内容
影响因子：
7.2
作者：
Blasko, Imrich;Kemmler, Georg;Fischer, Peter
通讯作者：
Fischer, Peter
影响因子：
15.8
作者：
Ioannidis, JPA
通讯作者：
Ioannidis, JPA
自身抗体作为血液生物标记物在早期检测和诊断帕金森病方面的潜在作用
影响因子：
4.4
作者：
DeMarshall, Cassandra A.;Han, Min;Nagele, Robert G.
通讯作者：
Nagele, Robert G.
DOI：
10.1016/j.dadm.2015.12.001
发表时间：
2016
期刊：
Alzheimer's & dementia (Amsterdam, Netherlands)
影响因子：
--
作者：
Gupta VB;Doecke JD;Hone E;Pedrini S;Laws SM;Thambisetty M;Bush AI;Rowe CC;Villemagne VL;Ames D;Masters CL;Macaulay SL;Rembach A;Rainey-Smith SR;Martins RN;AIBL Research Group
通讯作者：
AIBL Research Group
影响因子：
64.8
作者：
Collins, Francis S.;Tabak, Lawrence A.
通讯作者：
Tabak, Lawrence A.